A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer

被引：0
|
作者：
Taisuke Mori
Kenichi Hosokawa
Yoshiyuki Kinoshita
Ai Watanabe
Takeshi Yamaguchi
Haruo Kuroboshi
Yoshiko Kato
Jinsuke Yasuda
Hiroyuki Fujita
Yoshinori Nakata
Hideo Honjo
机构：
[1] Kyoto Prefectural University of Medicine,Department of Obstetrics and Gynecology
来源：
International Journal of Clinical Oncology | 2007年 / 12卷
关键词：
Ovarian cancer; Docetaxel; Paclitaxel; Toxicity; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：205 / 211
页数：6
相关论文
共 50 条
  • [41] THE PRESENCE OF M2 MACROPHAGES IN OVARIAN CANCER IS INFLUENCED BY TUMOR STAGE AND GRADE, NOT BY THE ADMINISTRATION OF PACLITAXEL-CARBOPLATIN: A PILOT STUDY
    Baert, T.
    Mathivet, T.
    Van Hoylandt, A.
    Vergote, I.
    Coosemans, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1282 - 1282
  • [42] WEEKLY PACLITAXEL-CARBOPLATIN IS EFFECTIVE IN PLATIN-RESISTANT AND WEEKLY PACLITAXEL-RESITANT OVARIAN CANCER
    Salihi, R.
    Leunen, K.
    Neven, P.
    Berteloot, P.
    Amant, F.
    Vergote, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 355 - 355
  • [43] PACLITAXEL-CARBOPLATIN WITH THE ORAL IAP INHIBITOR DEBIO1143 IN A SUBSET OF PATIENTS WITH RECURRENT EPITHELIAL OVARIAN CANCER (EOC): PHASE I
    Ray-Coquard, I.
    Le Tourneau, C.
    Isambert, N.
    Gomez-Roca, C. A.
    Cassier, P.
    Sablin, M. P.
    Purcea, D.
    Rouits, E.
    Schusterbauer, C.
    Vuagniaux, G.
    Zanna, C.
    Fumoleau, P.
    Delord, J. P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 875 - 876
  • [44] Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer
    Micha, JP
    Goldstein, BH
    Rettenmaier, MA
    Mattison, J
    Graham, C
    Birk, CL
    Brown, JV
    GYNECOLOGIC ONCOLOGY, 2004, 94 (03) : 719 - 724
  • [45] Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer
    Huinink, WWT
    vanWarmerdam, LJC
    Helmerhorst, TJ
    Schaefers, MCW
    Beijnen, JH
    Rodenhuis, S
    ANNALS OF ONCOLOGY, 1997, 8 (04) : 351 - 354
  • [46] Paclitaxel with carboplatin for the treatment of ovarian cancer
    Neijt, JP
    Lund, B
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 2 - 4
  • [47] Comparison of Efficacies of Dose Dense Paclitaxel Plus Carboplatin and Conventional Paclitaxel Plus Carboplatin in the Treatment of Epithelial Ovarian Cancer
    Sunar, Veli
    Korkmaz, Vakkas
    Aslan, Koray
    Kose, Caner
    Sarici, Furkan
    Arik, Zafer
    Meydanli, Mehmet Mutlu
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2021, 31 (04): : 239 - 245
  • [48] OVERALL SURVIVAL AND HOSPITALIZATION RATES IN MEDICARE PATIENTS DIAGNOSED WITH ADVANCED NSCLC TREATED WITH BEVACIZUMAB- PACLITAXEL-CARBOPLATIN VS PACLITAXEL-CARBOPLATIN: A RETROSPECTIVE COHORT STUDY
    Langer, Corey J.
    Ravelo, Arliene
    Hazard, Sebastien
    Guerin, Annie
    Latremouille-Viau, Dominick
    Ionescu-Ittu, Raluca
    Wu, Eric Q.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S877 - S877
  • [49] CARBOPLATIN AND PACLITAXEL IN OVARIAN-CANCER
    OZOLS, RF
    SEMINARS IN ONCOLOGY, 1995, 22 (03) : 78 - 83
  • [50] Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
    Neijt, JP
    Engelholm, SA
    Tuxen, MK
    Sorensen, PG
    Hansen, M
    Sessa, C
    de Swart, CAM
    Hirsch, FR
    Lund, B
    van Houwelingen, HC
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3084 - 3092
12345